Financial Data and Key Metrics Changes - The company reported total revenue of $15.7 million, a decrease of $900,000 or 5% year over year [14] - Gross profit decreased by $2.4 million or 20% to $9.4 million compared to the previous year [15] - Gross margin was 60.1% of revenue, down from 71.5% in the previous year [17] - Net loss attributable to stockholders was $11.7 million or $8.03 per share, compared to a net loss of $20 million or $30.93 per share for the previous year [18] - Adjusted EBITDA loss was $8.8 million compared to an adjusted EBITDA loss of $4.1 million for the previous year [18] Business Line Data and Key Metrics Changes - Total systems and subscription revenue grew by 20% in the second quarter [5] - Cash system sales in the U.S. represented 65% of total U.S. system sales, up from 58% the previous year [9] - Revenue from the company's internal lease program, Venus Prime, accounted for approximately 37% of total systems revenue, compared to 34% in the prior year [15] Market Data and Key Metrics Changes - U.S. revenue increased by 5% year over year, while international sales declined by 18% [6] - The company noted that customer financing pressures and economic uncertainty are impacting system adoption [7] - The international business is particularly exposed to macroeconomic headwinds, including tariffs affecting distributor demand [8] Company Strategy and Development Direction - The company announced a definitive agreement to sell the Venus Hair business for $20 million, allowing a focus on the global medical aesthetics business [10] - The strategic transaction is expected to improve revenue growth, lower operating expenses, and enhance cash flow [10] - The company aims to transition to higher quality cash revenues and is focused on launching a new body device by early 2026 [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed that the year-over-year results indicate potential revenue stabilization despite a challenging capital equipment environment [6] - The company is managing cash burn through disciplined cost management and targeted investments for long-term growth [13] - Due to ongoing market conditions and trade disruptions, the company is not providing full-year 2025 financial guidance [20] Other Important Information - The company has made significant progress in improving its balance sheet, with cash and cash equivalents of $4.9 million and total debt obligations reduced to approximately $34.3 million [19] - The company exchanged $17.5 million of subordinated convertible notes for preferred stock, enhancing its financial profile [20] Summary of Q&A Session - There was no live Q&A session due to international travel conflicts, and all follow-up questions were directed to the investor inquiries email address [21]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $13.6 million, down $3.8 million or 22% year over year, primarily due to delays in system sales and distributor ordering patterns [11][12] - Gross profit decreased by $2.9 million or 25% to $8.8 million, with gross margin at 64.2% compared to 66.6% in the same quarter of the previous year [13][14] - Net loss attributable to stockholders was $12.4 million or $17.44 per share, compared to a net loss of $9.8 million or $16.91 per share in the first quarter of 2024 [15] Business Line Data and Key Metrics Changes - Systems revenue saw a 25% decrease, with a 25% decline in lease systems revenue as well [12][14] - Cash system sales in the U.S. represented 80% of total U.S. system sales, up from 75% the previous year, indicating a strategic shift towards higher quality cash revenues [6][7] Market Data and Key Metrics Changes - International revenue decreased by 29%, while U.S. revenue declined by 16.5% year over year, reflecting challenges in both domestic and international markets [12] - The global capital equipment environment remains uncertain, affecting customer financing and system adoption [5][9] Company Strategy and Development Direction - The company is focusing on transitioning to higher quality cash revenues and enhancing its long-term profitability profile [6][7] - Plans to launch a next-generation body contouring device in the second half of 2025, developed based on customer feedback [30][31] - The company is managing cash burn through disciplined cost management and targeted investments [9] Management's Comments on Operating Environment and Future Outlook - Management noted that economic uncertainty and higher interest rates are impacting customer purchasing patterns, leading to delays in closing deals [5][26] - The company does not provide full-year 2025 financial guidance but expects sequential revenue growth in the second quarter [18] Other Important Information - The company improved its balance sheet by converting $11 million of debt to equity and secured a new bridge loan amendment [10][17] - Total debt obligations decreased from approximately $39.7 million to $35.5 million [17] Q&A Session Summary Question: Impact of tariffs on international business - Management indicated that a 10% tariff on products sourced from Israel could impact gross margins by 11.5% in 2025 and 22.5% in 2026, but the overall impact is expected to be modest and manageable through pricing [22][23][25] Question: Delays in sales contracts - Delays in closing contracts were attributed to economic conditions affecting both U.S. sales and international distributor orders, with many deals pushed into the second quarter [26][28] Question: Update on next-gen body contouring device - The launch of the next-gen body contouring device is expected in early second half of 2025, with significant market uptake anticipated based on customer excitement [30][31]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $13.6 million, down $3.8 million or 22% year over year [11] - Gross profit decreased by $2.9 million or 25% to $8.8 million, with gross margin at 64.2% compared to 66.6% in the same quarter of the previous year [13][14] - Net loss attributable to stockholders was $12.4 million or $17.44 per share, compared to a net loss of $9.8 million or $16.91 per share in the first quarter of 2024 [15] - Adjusted EBITDA loss for the first quarter was $8.3 million, compared to a loss of $5.1 million in the prior year [15] - Cash and cash equivalents as of March 31, 2025, were $3.2 million, with total debt obligations reduced to approximately $35.5 million [16][17] Business Line Data and Key Metrics Changes - Systems revenue decreased by 25%, with a 25% decrease in lease systems revenue as well [12] - The percentage of total systems revenue from internal lease programs was approximately 25%, unchanged from the prior year [12] Market Data and Key Metrics Changes - International revenue decreased by 29%, while U.S. revenue decreased by 16.5% year over year [12] - The global capital equipment environment remains uncertain, affecting customer system adoption in both U.S. and international markets [6][8] Company Strategy and Development Direction - The company is focusing on transitioning to higher quality cash revenues, with cash system sales in the U.S. representing 80% of total U.S. system sales [7] - Plans to evolve the portfolio and launch a new body device in the second half of 2025 are underway [9] - The company is managing cash burn through disciplined cost management and targeted investments for long-term growth [9] Management's Comments on Operating Environment and Future Outlook - Management noted that customer financing pressures, economic uncertainty, and tighter credit markets are impacting system adoption [6] - The company does not provide full-year 2025 financial guidance but expects sequential revenue growth in the second quarter [18] Other Important Information - The company enhanced its balance sheet by converting $11 million of debt to equity and secured a new bridge loan amendment [10][17] - The company is actively evaluating strategic alternatives to maximize shareholder value amid current market conditions [18] Q&A Session Summary Question: Impact of tariffs on international business - Management indicated that a 10% tariff on products sourced from Israel could impact gross margins by 11.5% in 2025 and 22.5% in 2026, but the overall impact is expected to be modest and manageable through pricing [20][22][24] Question: Timing of delayed sales contracts - Delays in closing sales contracts were attributed to economic hesitancy affecting both U.S. sales and international distributor orders [27][29] Question: Update on next-gen body contouring device - The launch of the next-gen body contouring device is expected in the early part of the second half of 2025, with significant market uptake anticipated based on customer feedback [30][31][32]